Hybrid Meeting 2021

Thursday, 18 November 2021

Royal College of Physicians of Edinburgh

Hybrid Meeting 2021

 

Overview

SHARP for over 30 years has been at the forefront of the prevention of cardiovascular disease in Scotland. As we emerge from the effects of the COVID-19 pandemic our exciting educational programme continues with our November 2021 meeting.

Atrial fibrillation is a major risk factor for stroke. We will address both its detection and management, how to balance the benefit of prevention versus the risks and what is new in respect of national clinical guidance. The long term mortality and morbidity effects of coronary artery disease remains a major problem for society so it is both appropriate and important using a personalised approach, to examine recent therapeutic developments of heart failure in improving clinical outcomes.

We have become accustomised in the past two years to the benefits of technology enhanced consulting but wearable technology in the detection of heart disease continues to develop apace. Those attending the meeting will learn the role of technology in diagnosis and importantly what to do when faced with a printout from a patient using the latest ‘gizmo’.

We always need to look forward and more especially after a difficult two years. We are fortunate to have as a speaker, a worldwide expert of how the use of data will inform the management of patients with heart and vascular disease in the years ahead.

Finally, we are very proud of our continuing role in promoting the SHARP prize in the field of cardiovascular disease in order to showcase the work of young health professionals and helping to support and enhance their careers.

 

Sponsors

 

This event was funded by the companies mentioned through event sponsorship and sponsored sessions for which we are very grateful.

Other than their own sessions, these companies had no input into the design or content of the agenda but were in attendance on the day. Furthermore, the Bristol-Myers Squibb/Pfizer Alliance had funded and organised the sponsored lunchtime session on the agenda.

 

Presentations

The ASSIGN SCORE: here and now, and where next?

Professor Hugh Tunstall-Pedoe

Emeritus Professor and Senior Research Fellow, University of Dundee

Presentation

Dr Michelle Collister-Bartlett

 

Summary by

SHARP Trustee

 

Presentation by

Causal AI: Personalizing Estimation of Cardiovascular Risk based on Cumulative Exposure to the Causes of Atherosclerosis

Professor Brian Ference

Director of Research (Professor) in Translational Therapeutics & Executive Director of the Centre for Naturally Randomized Trials, University of Cambridge

Dr Michelle Collister-Bartlett

 

Summary by

SHARP Trustee

 

Presentation by

Statinwise: a series of n-of-1 trials to assess muscle symptoms

Professor Liam Smeeth

Director of London School of Hygiene & Tropical Medicine

Presentation

Dr Michelle Collister-Bartlett

 

Summary by

SHARP Trustee

 

Presentation by

Debate: Should Scotland adopt the 2019 ESC/EAS guidelines for lipid management?

Professor Chris Packard & Dr Michael Murphy

Professor Packard: Honorary Senior Research Fellow, Institute of CV & Medical Sciences, University of Glasgow
Dr Murphy: Clinical Reader, School of Medicine, University of Dundee

Presentation

Dr Michelle Collister-Bartlett

 

Summary by

SHARP Trustee

 

Presentation by

siRNA based therapeutics for population health – the Inclisiran story

Professor Kosh Ray

Chair in Public Heath (Clinical), Department of Public Health & Primary Care, Imperial College London

Presentation

Dr Michelle Collister-Bartlett

 

Summary by

SHARP Trustee

 

Presentation by

Opening Keynote Lecture: An Update on VTE for Cardiologists (Session sponsored by Bristol-Myers Squibb/Pfizer)

Dr Ander Cohen

Consultant Physician, Guy’s and St Thomas’ NHS Foundation Trust

Presentation

Dr Michelle Collister-Bartlett

 

Summary by

SHARP Trustee

 

Presentation by

Renal Outcome Trial Overview and Implementation – Product Specific presentation (Session sponsored by AstraZeneca)

Professor David Wheeler

Professor of Nephrology, University of College London

Presentation

Dr Michelle Collister-Bartlett

 

Summary by

SHARP Trustee

 

Presentation by

Community and individual detection of Atrial Fibrillation. The tip of the iceberg?

Professor Lis Neubeck

Head of the Centre for Cardiovascular Health, School of Health and Social Care, Edinburgh Napier University

Presentation

Dr Michelle Collister-Bartlett

 

Summary by

SHARP Trustee

 

Presentation by

The rise and rise of wearable technology, and what to do with it

Dr Carmel McEniery

Senior Research Associate, University of Cambridge

Presentation

Dr Michelle Collister-Bartlett

 

Summary by

SHARP Trustee

 

Presentation by

David on Goliath’s shoulders – how big data will inform healthcare

Professor Calum MacRae

Executive Director, One Brave Idea, PI, Apple Heart & Movement Study

Summary
Presentation

N/A

 

Summary by

N/A

 

Presentation by

 

SHARP Prize

Prognostic Value of Clinical and Genomic Data on Predicting Major Adverse Cardiovascular Events (MACE)

Ivy Ho

School of Medicine, University of Dundee, Dundee, UK

Winner of Best Poster for Non-Lipid Theme

Audit of patient selection for Familial Hypercholesterolaemia (FH) genetic testing over a 2-year period with retrospective comparison of the Simon-Broome criteria vs the Dutch Lipid Clinic Network (DLCN) criteria vs the Wales FH service genotype scoring criteria

Ruey Ping (Bernice) Teo

School of Medicine, University of Dundee, Dundee, UK

Winner of Best Poster for Lipid Theme

Sex and age specific performance of the ASSIGN risk score for the prediction of cardiovascular events in the general population

Tilly Hamilton

Medical School, University of Edinburgh, UK & BHF Centre for Cardiovascular Science, University of Edinburgh, UK

Winner of Best Presentation

Improving Detection and Management of Atrial Fibrillation after Ischaemic Stroke in Glasgow (IMPROVE-AF): A Quality Improvement Project

Fiona Johnston

Medical School, University of Glasgow, Glasgow, UK

Pirfenidone improves insulin sensitivity & cardiac function in high-fat diet-induced obese and insulin-resistant mice

Vishal Musale

School of Medicine, University of Dundee, Dundee, UK

Magnesium Sulphate Treatment During Hypertensive Pregnancy Improves Maternal but not Fetal Outcomes in Rats

Kayley. Scott

Institute of Cardiovascular & Medical Sciences, University of Glasgow, Scotland, UK

Relationship Between Cardiovascular Disease Pathology and Fatal Opioid and Other Sedative Overdose: A Post-Mortem Investigation and Pilot Study

Abdulmalik Zuhair Arab

School of Medicine, University of Dundee, UK

Determining the mechanism of myocardial injury and role of coronary disease in type 2 myocardial infarction: DEMAND-MI

Anda Bularga

Centre for Cardiovascular Science, University of Edinburgh, UK

Cumulative atherosclerotic burden in patients with angina and non-obstructive coronary artery disease (ANOCA)

Jaclyn Carberry

British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK

Rapid Access Chest Pain Clinic at St. Johns Hospital

Jacob Flapan

St. John’s Hospital, Livingstone, West Lothian, UK

Investigating the Association Between Type 2 Diabetes and Parkinson’s Disease Using Electronic Medical Records in the GoDARTS Bioresource

Dana L. Hutton

School of Medicine, University of Dundee, Dundee, UK

Evaluating Best Medical Therapy Provision in Peripheral Arterial Disease Patients: A Prospective Audit

Peter Ishak

Vascular Surgery Department, University Hospital Ayr & Undergraduate Medical School, University of Glasgow, UK

Evaluating clinical outcomes in temporal artery biopsy: a retrospective observational study

Peter Ishak

Vascular Surgery Department, University Hospital Ayr & Undergraduate Medical School, University of Glasgow, UK

Antianginal Therapy Before Percutaneous Coronary Intervention in Stable Angina—a retrospective audit

Kashan Ali & Mya Win

Department of Cardiology, Ninewells Hospital and Medical School, Dundee, UK

Association of lipoprotein(a) with CT coronary calcium score in a multi-ethnic, asymptomatic cohort of patients referred to a tertiary lipid clinic

Benjamin Low

Department of Cardiology, Imperial College Healthcare NHS Trust, London, UK

Finding Familial Hypercholesterolaemia After The Event

Calvin MacKinnon

Aberdeen Royal Infirmary, Aberdeen, UK

Understanding How Educational Interventions Improve Treatment Adherence In Patients With Familial Hypercholesterolaemia: A Systematic Review

Hannah Massey

Scottish Clinical Genetics Services in Aberdeen, UK

The routine clinical use of FIB-4 in lipid clinics

Ruvini NK Ranasinghe

Department of Clinical Biochemistry, King’s College Hospital, NHS Foundation Trust, London, UK

Audit of PCSK-9 Inhibitor Prescribing in GGC: Real Patient Data

Rufus Turner

Beatson West of Scotland Cancer Centre, UK

Differences in clinical characteristics, management and outcomes between men and women with type 2 myocardial infarction stratified by mechanism of injury

Emma Watkinson

University of Edinburgh, UK

A retrospective comparison of the Simon Broome and Dutch Lipid Clinic Network criteria for the diagnosis of Familial Hypercholesterolaemia in the Glasgow Clyde sector

Kirsten Grant

Glasgow Royal Infirmary, UK

Poster

Genetic Testing for Hypertriglyceridaemia in the UK

Georgios Kounidas

University of Aberdeen, UK

Opportunities for Primary Prevention of Cardiovascular Disease observed through Incidental Findings of Elevated Lipid Profiles in Clinical Research Centre Trial Participants

Christine Almaden-Boyle & Mon M Oo

University of Dundee, UK

Troponin in the chronic coronary syndrome

Ryan Wereski

BHF/University Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK

Boehringer Ingelheim
Menarini
Astra Zeneca
Novo Nordisk
Bristol Myers Squibb
Pfizer

 

SHARP@dundee.ac.uk